Αρχική World News EMA Recommends Granting a Marketing Authorisation for Aumolertinib World News EMA Recommends Granting a Marketing Authorisation for Aumolertinib Από Ogkologos - 8 Ιανουαρίου, 2026 618 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of patients with EGFR-mutated NSCLC Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR What to Know About 3 Common Misconceptions Around Food and Cancer... 25 Απριλίου, 2023 Dual Antigen Targeting with Talquetamab plus Teclistamab in Patients with Relapsed... 20 Ιανουαρίου, 2025 Dress up that Salad! 21 Δεκεμβρίου, 2020 Can Artificial Intelligence Help See Cancer in New, and Better, Ways? 22 Μαρτίου, 2022 Φόρτωση περισσοτέρων HOT NEWS Study Suggests Statins May Help Keep Breast Cancer from Spreading to... Indigenous Women with Early Stage Breast Cancer Get Mastectomies at Higher... Increased Risk of Cancer in Early Life Among Individuals with Autism... Woman Donates 500 Care Packages To Breast Cancer Patients